You're quite right to point out, as you just did, that it is one of the principles the minister would be required to consider when moving forward on national universal pharmacare.
With regard to the others—proposed paragraphs (a), (b), (c) and (d)—and then speaking specifically about appropriate use, one of the reasons that this wording is there is that there are numerous studies to show that in fact there are issues with improper prescribing or over-prescribing, and you're probably aware of a lot of efforts around de-prescribing, in particular with older patients.
The idea behind the mention of “appropriate use” is to ensure the safety of patients. When the right drug is given to the right patient at the right time, it can also bring some savings, both for the system and for the patient.
The other thing I'll note is that the reference is also made in the context of the work that would be done by the CDA. A similar reference is made in proposed section 7 of the legislation, and then, of course, there's the work that would be done by the CDA to produce the appropriate use strategy.
Finally, just to close, I mentioned earlier that in working toward the CDA, there was the CDA transition office, and as part of that, there has been a fair bit of work done already in the context of appropriate use strategy, and there will be a publication of that recommendation from that expert committee very shortly.
Thank you.